Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Nab-paclitaxel + S-1/LV vs Oxaliplatin in Metastatic Pancreatic Cancer
NCT05026905Phase 2Active, not recruiting
- Sponsor
- National Health Research Institutes
- Start
- Dec 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur and oxaliplatin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by National Health Research Institutes. Primary endpoint: Best objective response rate at 6 years. Started Dec 2021; status: active, not recruiting.
02
Drugs
tegafuroxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05026905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05026905.